Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04634877
Title Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

endometrial carcinoma

uterine carcinosarcoma

Therapies

Carboplatin + Paclitaxel

Cisplatin + Paclitaxel

Carboplatin + Docetaxel

Cisplatin + Paclitaxel + Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Cisplatin + Docetaxel + Pembrolizumab

Cisplatin + Docetaxel

Carboplatin + Docetaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT

Additional content available in CKB BOOST